Web Analytics

3 Latest Announced Rounds

  • $70,000,000
    Series A

    3 Investors

    Technology, Information and Internet
    Aug 7th, 2025
  • $2,500,000
    Pre-Seed

    4 Investors

    Space Research and Technology
    Aug 7th, 2025
  • $9,300,000
    Seed

    5 Investors

    Internet Marketplace Platforms
    Aug 7th, 2025
$885.86M Raised in 39 Funding Rounds in the past 7 Days - View All

Funding Round Profile

Proniras Corporation

start up
United States - Seattle, Washington
  • 02/02/2024
  • Series B
  • $4,650,000

Proniras Corporation is a clinical-stage biotechnology developing novel small-molecule therapeutics for the treatment of substance use and specialty central nervous system disorders. The Company’s lead program PRN-001-01 (tezampanel) is being clinical developed as a treatment option for opioid withdrawal and related disorders of addiction. Although effective treatments exist for opioid addiction, painful and difficult withdrawal is one of the primary reasons why current treatment fails, and relapse occurs. By alleviating the symptoms associated with opioid withdrawal, Proniras hopes to help patients successfully discontinue opioid usage and sustain an opioid-free life. Proniras was formed in 2017 by Accelerator Life Science Partners.


Related People

Christopher ToombsCo Founder

Christopher Toombs United States - Seattle, Washington

N/A